Globe Newswire06.09.20
CurvaFix Inc., a developer of medical devices to repair fractures in curved bones, has appointed Trevor Moody and Jeffrey Rydin to its Board of Directors.
Moody is a partner at M.H. Carnegie & Co., an Australian private equity and venture capital firm, as well as president of TM Strategic Advisors LLC, a management consultancy serving the boards, investors and senior management of emerging and established medical technology companies. Rydin currently serves as director of Alphatec Spine, which develops spinal implants, and DuraStat LLC, a private company focused on dural repair.
“On behalf of CurvaFix, I’m extremely pleased to welcome Trevor and Jeffrey to our board of directors,” said Steve Dimmer, CEO of CurvaFix. “They bring years of expertise in key areas including global sales, development, commercialization and funding of innovative medical technologies, and they join us at a very exciting time as we gear up for commercialization in orthopedic trauma.”
Moody was previously a general partner at Frazier Healthcare Ventures, a firm with more than $2 billion under management, where he co-led the medical device team. In addition to several boards including ElectroCore, Renew Medical, Serene Medical, Simplify Medical, Cardiac Dimensions and EBR Systems. He is the previous board chair of the Center for Infectious Disease Research. Moody graduated from the Massachusetts Institute of Technology with a M.S. in science and management, and from the University of Southern Queensland with a B.Eng. in engineering.
Rydin was most recently the chief sales officer of Ellipse Technologies, until its $410 million acquisition by NuVasive. Prior to this, he served as the president of global sales at NuVasive where he was responsible for building worldwide sales to $600 million annually. Rydin has also held senior executive sales positions at DePuy Spine, Orquest, Symphonix Devices, General Surgical Innovations, Baxter Healthcare, and US Surgical Corporation. He earned a bachelor of arts degree in social ecology from the University of California, Irvine.
The board appointments follow the company's announcement last fall of the completion of the first surgical procedure using the CurvaFix Intramedullary Rodscrew to repair a pelvic fracture. The surgery was performed by orthopedic trauma surgeon Kelly Lefaivre, M.D., M.Sc., FRCSC, associate professor at the University of British Columbia, Vancouver, British Columbia, as part of the CurvaFix sponsored RESTORE Clinical Study.
The CurvaFix Rodscrew System received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in the first half of 2019.
Moody is a partner at M.H. Carnegie & Co., an Australian private equity and venture capital firm, as well as president of TM Strategic Advisors LLC, a management consultancy serving the boards, investors and senior management of emerging and established medical technology companies. Rydin currently serves as director of Alphatec Spine, which develops spinal implants, and DuraStat LLC, a private company focused on dural repair.
“On behalf of CurvaFix, I’m extremely pleased to welcome Trevor and Jeffrey to our board of directors,” said Steve Dimmer, CEO of CurvaFix. “They bring years of expertise in key areas including global sales, development, commercialization and funding of innovative medical technologies, and they join us at a very exciting time as we gear up for commercialization in orthopedic trauma.”
Moody was previously a general partner at Frazier Healthcare Ventures, a firm with more than $2 billion under management, where he co-led the medical device team. In addition to several boards including ElectroCore, Renew Medical, Serene Medical, Simplify Medical, Cardiac Dimensions and EBR Systems. He is the previous board chair of the Center for Infectious Disease Research. Moody graduated from the Massachusetts Institute of Technology with a M.S. in science and management, and from the University of Southern Queensland with a B.Eng. in engineering.
Rydin was most recently the chief sales officer of Ellipse Technologies, until its $410 million acquisition by NuVasive. Prior to this, he served as the president of global sales at NuVasive where he was responsible for building worldwide sales to $600 million annually. Rydin has also held senior executive sales positions at DePuy Spine, Orquest, Symphonix Devices, General Surgical Innovations, Baxter Healthcare, and US Surgical Corporation. He earned a bachelor of arts degree in social ecology from the University of California, Irvine.
The board appointments follow the company's announcement last fall of the completion of the first surgical procedure using the CurvaFix Intramedullary Rodscrew to repair a pelvic fracture. The surgery was performed by orthopedic trauma surgeon Kelly Lefaivre, M.D., M.Sc., FRCSC, associate professor at the University of British Columbia, Vancouver, British Columbia, as part of the CurvaFix sponsored RESTORE Clinical Study.
The CurvaFix Rodscrew System received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in the first half of 2019.